Global Neuromodulation Devices Market

Neuromodulation Devices Market Size, Share, Growth Analysis, By Product (Spinal Cord Stimulators, Deep Brain Stimulators), By Application (E Parkinson’s Disease, Chronic Pain), By End Use (Hospitals & Ambulatory Surgery Centers, Clinics & Physiotherapy Centers), By Region - Industry Forecast 2025-2032


Report ID: SQMIG35A2716 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 93 | Figures: 76

Neuromodulation Devices Market Regional Insights

The neuromodulation market size in North America was at its highest level, and the region's dominance is mostly attributable to its patients' higher rates of diagnosis and treatment as well as their greater use of neuromodulation devices to treat chronic illnesses. The second-largest market share belonged to Europe. The demand for these devices is being fueled by a strong healthcare infrastructure as well as an increase in non-invasive device approvals in the region.

Asia-Pacific is expected to have a greater CAGR than other regions throughout the forecast period. The market is expected to grow as a result of factors such as improving diagnosis and treatment rates, expanding healthcare infrastructure, and rising per capita healthcare spending. Neurostimulation devices have a lot of potential in the underdeveloped markets of Latin America and the Middle East and Africa. The neurostimulation devices market is anticipated to develop due to the entry of industry players through direct and indirect presence in these regions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Neuromodulation Devices Market size was valued at USD 5.13 billion in 2022 and is poised to grow from USD 5.58 billion in 2023 to USD 10.87 billion by 2031, growing at a CAGR of 8.7% during the forecast period (2024-2031). 

The neuromodulation devices market is highly concentrated, with the top 3–4 companies holding more than 90% of the market. With a varied portfolio, great brand recognition, widespread geographic reach, and a robust distribution network, Medtronic has been able to dominate the industry. Abbott and Boston Scientific Corporation have both experienced a decline in market share over the past few years as a result of delays in the introduction of cutting-edge products in the spinal cord stimulation and other key categories. 'Medtronic ', 'Synapse Biomedical ', 'Abbott Laboratories ', 'Boston Scientific Corporation ', 'LivaNova PLC ', 'Nevro Corp. ', 'NeuroSigma Inc. ', 'NeuroPace Inc. ', 'Cyberonics Inc. ', 'NDI Medical LLC ', 'NeuroMetrix Inc. ', 'NeuroVista Corporation ', 'Neuronetics Inc. ', 'BioControl Medical ', 'SPR Therapeutics ', 'MicroTransponder Inc. ', 'Soterix Medical Inc. ', 'BrainsWay Ltd. ', 'Saluda Medical Pty Ltd '

The global neuromodulation devices market is driven by a number of reasons. One of the key factors propelling the neuromodulation devices market is the increase in health issues. Due to the exceptional capacity to offer comfort in various kinds of illnesses, neuromodulation devices have grown in favor over the years for treating chronic pain, shoulder pain, headaches, and brain injuries. In addition to treating depression, digestive, and sleeping issues, neuromodulation devices are used. Therefore, the business for neuromodulation devices is being driven by the widespread use of these devices to treat a variety of disorders.

A sizable fraction of patients with long-term illnesses, such as chronic back pain, depression, epilepsy, and sleep apnea, among others, are showing signs of drug and medicine resistance. Resistance is evident in the treatment's slow progression and any outcomes that are delayed or insufficient. The market trends for neuromodulation devices are being driven by healthcare practitioners turning their attention to neurostimulation methods for the management of chronic illnesses as a result.

The neuromodulation market size in North America was at its highest level, and the region's dominance is mostly attributable to its patients' higher rates of diagnosis and treatment as well as their greater use of neuromodulation devices to treat chronic illnesses. The second-largest market share belonged to Europe. The demand for these devices is being fueled by a strong healthcare infrastructure as well as an increase in non-invasive device approvals in the region.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Neuromodulation Devices Market

Report ID: SQMIG35A2716

$5,300
BUY NOW GET FREE SAMPLE